+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Pancreatic Cancer Therapeutics Market 2019-2023 - Product Image

Global Pancreatic Cancer Therapeutics Market 2019-2023

  • ID: 4745529
  • Report
  • December 2018
  • Region: Global
  • 115 pages
  • TechNavio
UP TO OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Eli Lilly
  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer
  • Shire
  • MORE
Availability of improved diagnostic modalities to drive growth in the market. To combat the shortcomings in the prognosis of pancreatic cancer, advanced diagnostic aids based on the principles of complementary DNA (cDNA) fingerprinting, PCR, and DNA microarray, and molecular profiling are being developed. Analysts have predicted that the pancreatic cancer therapeutics market will register a CAGR of more than 8% by 2023.

Market Overview

Robust pipeline and new drug approvals

The pipeline for the treatment of pancreatic cancer includes novel therapeutic approaches, including vaccines, gene therapy, stem cell therapy, and targeted therapy products.

High cost of treatments

Pancreatic cancer requires long term treatment, which increases the treatment cost and the economic burden on patients.

For the detailed list of factors that will drive and challenge the growth of the pancreatic cancer therapeutics market during the 2019-2023, view this report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Pfizer and Shire, the competitive environment is quite intense. Factors such as the robust pipeline and new drug approvals and the availability of improved diagnostic modalities, will provide considerable growth opportunities to pancreatic cancer therapeutics manufactures. Eli Lilly, F. Hoffmann-La Roche, Novartis, Pfizer, and Shire are some of the major companies covered in this report.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Eli Lilly
  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer
  • Shire
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Targeted therapy - Market size and forecast 2018-2023
  • Chemotherapy - Market size and forecast 2018-2023
  • Market opportunity by product
PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY TYPE
  • Exocrine pancreatic cancer
  • Endocrine pancreatic cancer
PART 10: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 14: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer
  • Shire
PART 15: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Years in consideration
Exhibit 02: Global oncology therapeutics market
Exhibit 03: Segments of global oncology therapeutics market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Therapies in late stage development for pancreatic cancer
Exhibit 07: Market definition - Inclusions and exclusions checklist
Exhibit 08: Market size 2018
Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2018
Exhibit 19: Product - Market share 2018-2023 (%)
Exhibit 20: Comparison by product
Exhibit 21: Targeted therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Targeted therapy - Year-over-year growth 2019-2023 (%)
Exhibit 23: Chemotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Chemotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by product
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 31: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 33: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 35: Key leading countries
Exhibit 36: Market opportunity
Exhibit 37: Decision framework
Exhibit 38: New drug approvals for pancreatic cancer
Exhibit 39: Patent expiration dates for therapies for pancreatic cancer
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Immunotherapy products under research
Exhibit 42: Combination therapies for pancreatic cancer
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: Eli Lilly - Vendor overview
Exhibit 49: Eli Lilly - Business segments
Exhibit 50: Eli Lilly - Organizational developments
Exhibit 51: Eli Lilly - Geographic focus
Exhibit 52: Eli Lilly - Segment focus
Exhibit 53: Eli Lilly - Key offerings
Exhibit 54: F. Hoffmann-La Roche - Vendor overview
Exhibit 55: F. Hoffmann-La Roche - Business segments
Exhibit 56: F. Hoffmann-La Roche - Organizational developments
Exhibit 57: F. Hoffmann-La Roche - Geographic focus
Exhibit 58: F. Hoffmann-La Roche - Segment focus
Exhibit 59: F. Hoffmann-La Roche - Key offerings
Exhibit 60: Novartis - Vendor overview
Exhibit 61: Novartis - Business segments
Exhibit 62: Novartis - Organizational developments
Exhibit 63: Novartis - Geographic focus
Exhibit 64: Novartis - Segment focus
Exhibit 65: Novartis - Key offerings
Exhibit 66: Pfizer - Vendor overview
Exhibit 67: Pfizer - Business segments
Exhibit 68: Pfizer - Organizational developments
Exhibit 69: Pfizer - Geographic focus
Exhibit 70: Pfizer - Segment focus
Exhibit 71: Pfizer - Key offerings
Exhibit 72: Shire - Vendor overview
Exhibit 73: Shire - Business segments
Exhibit 74: Shire - Organizational developments
Exhibit 75: Shire - Geographic focus
Exhibit 76: Shire - Key offerings
Exhibit 77: Validation techniques employed for market sizing
Exhibit 78: List of abbreviations
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Eli Lilly
  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer
  • Shire
  • MORE
Global Pancreatic Cancer Therapeutics Market 2019-2023

The analyst recognizes the following companies as the key players in the global pancreatic cancer therapeutics market: Eli Lilly, F. Hoffmann-La Roche, Novartis, Pfizer, and Shire.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the availability of improved diagnostic modalities.”

According to the report, one of the major drivers for this market is the robust pipeline and new drug approvals.

Further, the report states that one of the major factors hindering the growth of this market is the high cost of treatments.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer
  • Shire
Note: Product cover images may vary from those shown
Adroll
adroll